1. Nektar Therapeutics will participate in key investor conferences this month. 2. Presentations will focus on their clinical pipeline and future developments. 3. Webcast links for presentations are available on their investor website. 4. Company's lead candidate, NKTR-358, is in Phase 2b trials. 5. Nektar also has multiple projects in various stages of development.
Participation in investor conferences often boosts visibility, potentially attracting investment interest. Historical trends show positive market reactions to biotech presentations showcasing pipeline progress.
The announcement indicates ongoing development and engagement strategy, vital for investor confidence. Events like these can catalyze temporary price increases during and after presentations.
The upcoming conferences are soon, indicating immediate interest and potential stock movement. Past instances show stocks can react positively to short-term engagement events.
SAN FRANCISCO, Sept. 3, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York City and the Stifel Virtual Immunology and Inflammation Forum being held September 15-16, 2025.
The presentations will be accessible via the webcast links above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. Replays of the presentations will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow Nektar on LinkedIn.
Contact:
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
For Media:
Madelin Hawtin
LifeSci Communications
603-714-2638
mhawtin@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-two-investor-conferences-in-september-302545833.html
SOURCE Nektar Therapeutics